UNSPSC 51183617: Insulin porcine

This classification denotes a therapeutic insulin with the molecular formula C256H381N65O76S6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AVT680JB39, chemically known as insulin (ox), 8a-l-threonine-10a-l-isoleucine-, but more generally known as insulin porcine, which bears US NIH Compound Identifier 16131098. European Medicines Agency schedules insulin porcine or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02689MIG.

Most nations, for tariff purposes, schedule insulin porcine under HS 29371200. SMILES:.

UNSPSC 51183617 Insulin porcine is a Commodity code representing prescription pharmaceutical products that state and local healthcare systems and cooperative purchasing alliances procure through multi-vendor pharmaceutical supply agreements. The code captures insulin products sourced as part of broader generic multi-source pharmaceutical procurement, where state agencies and participating jurisdictions establish framework contracts with manufacturers to ensure reliable supply and negotiated pricing across multiple dispensing points — including correctional facilities, public health clinics, and hospital systems operated by state and local government.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP in January 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products, including insulin and related insulin products, for distribution across participating state and local government facilities in Minnesota, Oregon, and other member jurisdictions. The RFP due date is March 26, 2026, with evaluations weighted heavily toward price competitiveness (75 percent) and manufacturers required to supply detailed product information including National Drug Codes, pricing through authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co.), cGMP and Drug Supply Chain Security Act compliance, and insurance coverage including $5 million commercial general liability. The contract term is two years for new responders with optional extensions, effective July 1, 2026, and manufacturers must maintain contractual relationships with at least two of the three authorized wholesalers and demonstrate pricing flexibility through flat price, net price formats, or WAC-minus structures.